ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 1:00 PM ET.

A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, The webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit

Aclaris Therapeutics Contact:

Robert A. Doody Jr.

Vice President, Investor Relations

484-639-7235



EN
27/03/2023

Underlying

ACRSAclaris Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aclaris Therapeutics Inc.

 PRESS RELEASE
Free
ACRS Aclaris Therape...

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financi...

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - - Investigational New Drug (IND) Application for Lead ITK Inhibitor Candida...

February 26, 2026 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
ACRS ACLARIS THERAPEUTICS INC.
02/26/26 February 26, 2026 1 EN
 PRESS RELEASE
Free
ACRS Aclaris Therape...

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Pati...

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept (POC) trial of ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4Rα antibody, in asthma. This announcement follo...

February 24, 2026 1 EN
 PRESS RELEASE
Free
ACRS Aclaris Therape...

Aclaris Therapeutics to Participate in Two February Healthcare Confere...

Aclaris Therapeutics to Participate in Two February Healthcare Conferences WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in February 2026. On Thursday February 12, 2026, at 2:30 PM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Gug...

February 4, 2026 1 EN
 PRESS RELEASE
Free
ACRS Aclaris Therape...

Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates R...

Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) - ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced recent positive preclinical results from its potent and selective ITK/JAK3 inhibitor ATI-2138 in a mur...

January 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch